Email
Print
Toxoplasmosis Diagnostic Testing Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022-2027
Toxoplasmosis Diagnostic Testing Market Overview
The Toxoplasmosis Diagnostic Testing Market size is estimated to be $1.9 billion in 2021, growing at a CAGR of 7.3% during the forecast period 2022-2027. Toxoplasmosis is an ailment acquired from infection with a parasite termed Toxoplasma gondii (T. gondii). Nearly all people who are infected have no signs or symptoms and will not require treatment. Toxoplasmosis Diagnostic Testing typically involves serologic testing. A test that assesses immunoglobulin G (IgG) is utilized to conclude if a person has been infected. Congenital toxoplasmosis can lead to visual impairment, hearing loss, severe neurologic sequelae and demise in the infant. The Polymerase Chain Reaction (PCR) Testing segment is estimated to grow with the fastest CAGR of 8.1% during the forecast period 2022-2027 owing to the surging application of PCR testing on peripheral blood to detect cases of ocular toxoplasmosis and invasive disease in allogeneic stem cell recipients. The enhanced healthcare infrastructure across the world is set to drive the Toxoplasmosis Diagnostic Testing Market. The surging application of serologic diagnostic techniques for the diagnosis of Toxoplasmosis is set to propel the growth of the Toxoplasmosis Diagnostic Testing Industry during the forecast period 2022-2027. This represents the Toxoplasmosis Diagnostic Testing Industry Outlook.
Toxoplasmosis Diagnostic Testing Market Report Coverage
The “Toxoplasmosis Diagnostic Testing
Market Report - Forecast (2022-2027)” by Industry ARC, covers an
in-depth analysis of the following segments in the Toxoplasmosis Diagnostic Testing Market.
Key Takeaways
- Geographically, North America (Toxoplasmosis Diagnostic Testing market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027. This growth is owing to the increasing predominance of infectious ailments and the soaring awareness among individuals regarding the accessibility of progressive diagnostic techniques including serologic diagnostic testing techniques in the North American region.
- Toxoplasmosis Diagnostic Testing Market growth is being driven by the surging technological progress in toxoplasmosis diagnostic testing like touch-down -multiplex polymerase chain reaction (PCR), the extensive application of Indirect immunofluorescence (IIF) for diagnosis in humans and the expanding count of anti-infective medications. However, the soaring cost of toxoplasmosis tests and the dearth of awareness regarding parasitic infection are some of the major factors hampering the growth of the Toxoplasmosis Diagnostic Testing Market.
- Toxoplasmosis Diagnostic Testing Market Detailed Analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Toxoplasmosis Diagnostic Testing Market report.
Toxoplasmosis Diagnostic Testing Market: Market Share (%) by Region, 2021
For More Details On this report - Request For Sample
Toxoplasmosis Diagnostic Testing Market Segment Analysis - by Diagnostic Test
The Toxoplasmosis Diagnostic
Testing Market based on the diagnostic tests can be further segmented into Serological Tests, Polymerase Chain
Reaction (PCR) Testing, Amniocentesis, Ultrasound Scan, Magnetic
resonance imaging (MRI) and Brain Biopsy. The Serological Tests Segment held the largest Toxoplasmosis Diagnostic Testing market
share in 2021. This growth is owing to the surging application of serological
tests for the diagnosis of toxoplasmosis. The Toxoplasmosis Cerebrospinal Fluid
(CSF) Test detects the existence of T. gondii in the cerebrospinal fluid. The
heightening application of Confirmatory serologic testing for acute
toxoplasmosis is further propelling the growth of the Serological Tests segment.
Furthermore, the Polymerase Chain Reaction (PCR) Testing segment is
estimated to grow with the fastest CAGR of 8.1% during the forecast period 2022-2027
owing to the surging application of PCR testing on peripheral blood to detect
cases of ocular toxoplasmosis and invasive disease in allogeneic stem cell
recipients.
Toxoplasmosis Diagnostic Testing Market Segment Analysis - by End-use Industry
The Toxoplasmosis Diagnostic Testing Market based on the end-use industry can be further segmented into Hospitals, Pathology Laboratories, Clinics, Diagnostic Centers and Others. The Hospitals Segment held the largest Toxoplasmosis Diagnostic Testing market share in 2021. This growth is owing to the increasing inclination of patients towards hospitals for diagnosis of Toxoplasmosis. Serological testing is available in specialized hospitals equipped with progressive healthcare facilities.A Toxoplasma-positive reaction may be tinted by immunofluorescence (IFA). Prenatal brain imaging in congenital toxoplasmosis has been explored. Hospitals for ocular toxoplasmosis are available. The presence of advanced infrastructure and the effortless availability of qualified and skilled physicians and multidisciplinary teams in hospitals is further propelling the growth of this segment.
Furthermore, the Diagnostic Centers segment is
estimated to grow with the fastest CAGR of 8.3% during the forecast period 2022-2027 owing to the extensive
application of laboratory diagnosis for congenital toxoplasmosis and molecular
diagnosis of toxoplasmosis in diagnostic centers.
Toxoplasmosis Diagnostic Testing Market Segment Analysis - by Geography
The Toxoplasmosis Diagnostic Testing Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Toxoplasmosis Diagnostic Testing Market) held the largest Toxoplasmosis Diagnostic Testing market share with 39% of the overall market in 2021. The growth of this region is owing to the increasing predominance of infectious ailments like Toxoplasmosis, in the North American region. A Toxoplasma-positive reaction may be dyed by immunofluorescence (IFA). Prenatal brain imaging in congenital toxoplasmosis has been examined. The soaring awareness among people regarding the accessibility of progressive diagnostic techniques is further propelling the growth of the Toxoplasmosis Diagnostic Testing Industry, thereby contributing to the Toxoplasmosis Diagnostic Testing Industry Outlook, in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the enormous population in the Asia-Pacific region. The surging modernization of the healthcare infrastructure in emerging economies is further fuelling the progress of the Toxoplasmosis Diagnostic Testing Market in the Asia-Pacific region.
Toxoplasmosis Diagnostic Testing Market Drivers
Surging Applications of Serologic Tests for the Diagnosis of Toxoplasmosis are Projected to Drive the Growth of Toxoplasmosis Diagnostic Testing Market:
As per the Centers for Disease Control And Prevention (CDC), Toxoplasmosis is brought about by the protozoan parasite Toxoplasma gondii. In the U.S., it is supposed that 11% of the populace, 6 years and older have been infected with Toxoplasma. The diagnosis of toxoplasmosis can be identified by serological tests, polymerase chain reaction (PCR), histological demonstration of the parasite and/or its antigens (like immunoperoxidase stain) or isolation of the organism. Distinct serological tests frequently assess distinct antibodies that possess rare patterns of rising and falling with time subsequent to infection. An integration of serological tests is repeatedly needed to set up whether an individual has been more likely infected in the distant past or has been currently infected. An IgM test is utilized to assist in concluding whether a patient has been infected currently or in the distant past. Owing to the considerable likelihood of misinterpreting a positive IgM test outcome, confirmatory testing needs to be carried out. The surging applications of serologic tests for the diagnosis of Toxoplasmosis are therefore fuelling the growth of the Toxoplasmosis Diagnostic Testing Market during the forecast period 2022-2027.
Extensive Applications of Toxoplasmosis Cerebrospinal Fluid Test are Expected to Boost the Growth of the Toxoplasmosis Diagnostic Testing Industry:
Prenatal brain imaging in congenital toxoplasmosis has been investigated. The Toxoplasmosis Cerebrospinal Fluid (CSF) Test discovers the existence of T. gondii in the cerebrospinal fluid (CSF). Toxoplasmosis is an ailment following infection by the microscopic parasite Toxoplasma gondii (T. gondii). T. gondii is very typical all through the world. In certain nations, it may infect 95% of the populace. The Toxoplasmosis Cerebrospinal Fluid (CSF) Test detects the existence of T. gondii in the cerebrospinal fluid. It can perform this in two distinct ways:
- Detection of particular antibodies developed by the immune system upon exposure to T. gondii. The existence of T. gondii-specific IgM antibodies signifies recent or current exposure. The existence of T. gondii-specific IgG antibodies signifies a past exposure
- Detection of genetic material belonging to T. gondii: A technique termed PCR is utilized to detect traces of specific DNA that T. gondii is recognized to possess
The extensive applications of the Toxoplasmosis Cerebrospinal Fluid Test are therefore driving the growth of the Toxoplasmosis Diagnostic Testing Industry, thereby contributing to the Toxoplasmosis Diagnostic Testing Industry Outlook during the forecast period 2022-2027.
Toxoplasmosis Diagnostic Testing Market Challenges
Diagnostic Challenges of Toxoplasmosis are Hampering the Growth of the Toxoplasmosis Diagnostic Testing Market:
There are nearly 400 to 4,000 cases of congenital toxoplasmosis every year in the U.S alone. Nearly all infected babies seem healthy at birth. They frequently do not develop symptoms until months, years or even decades later in life. Nearly all pregnant women in the U.S. are not routinely screened for toxoplasmosis and nearly all states do not screen infants for the infection. Without particular screening, toxoplasmosis is frequently hard to diagnose owing to signs and symptoms, when they happen, are similar to those of more typical ailments, like the flu and mononucleosis. Congenital toxoplasmosis imposes the challenge of early diagnosis as a complicated and neglected ailment. These issues are thus hampering the growth of the Toxoplasmosis Diagnostic Testing Market.
Toxoplasmosis Diagnostic Testing Industry Outlook
Novel product launches, acquisitions, collaborations and development of point-of-care devices under clinical trials to detect the presence of T. gondii are key strategies adopted by players in the Toxoplasmosis Diagnostic Testing Market. The top 10 companies in the Toxoplasmosis Diagnostic Testing market are:
- Abbott Laboratories
- Bio-Rad Laboratories Inc
- Affymetrix Inc.
- Beckman Coulter Inc.
- Biotest
- Cepheid Inc.
- GenBio
- Danaher Corporation
- Thermo Fisher Scientific
- Biomerica Inc.
Recent Developments
- In July 2021, Abbott declared the introduction of Panbio™ COVID-19 Antigen Self-Test for the detection of the SARS-CoV-2 virus with or without symptoms. In alignment with the present ICMR advisory on self-use, these tests will be made accessible to ramp up testing of symptomatic and asymptomatic individuals and contacts of confirmed coronavirus cases. Abbott will transfer millions of Panbio COVID-19 Rapid Antigen Tests accessible for self-use to ease the burden on healthcare systems in urban and rural India.
- In June 2021, Bio-Rad Laboratories, Inc. presently declared a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products. Under the terms of the agreement, Seegene, based in Seoul, Korea, will offer diagnostic tests for application on Bio-Rad's CFX96™ Dx Real-Time PCR System for U.S. markets pending clinical development and clearance from The U.S. Food & Drug Administration (FDA).
- In March 2020, Abbott accepted emergency use authorization (EUA) from the FDA for its molecular test for the identification of SARS-CoV-2, the virus that brings about COVID-19. The firm is deploying 150,000 laboratory tests instantly. Tests already have been sent to hospital and academic medical center labs in 18 states inclusive of Illinois, California, New York, Massachusetts and Washington. This concludes the Toxoplasmosis Diagnostic Testing Industry Outlook.
Relevant Reports:
Report Code: HCR 1359
Report Code: HCR 0827
Report Code: HCR 0084